xeroderma pigmentosum group C
|
MONDO_0010211 |
[An autosomal recessive inherited disorder caused by mutations in the XPC gene. This disease is characterized by increased sensitivity to sunlight with the development of carcinomas at an early age and is caused by a defect in nucleotide excision repair.] |
xeroderma pigmentosum
|
MONDO_0019600 |
[Xeroderma pigmentosum (XP) is a rare genodermatosis characterized by extreme sensitivity to ultraviolet (UV)-induced changes in the skin and eyes, and multiple skin cancers. It is subdivided into 8 complementation groups, according to the affected gene: classical XP (XPA to XPG) and XP variant (XPV).] |
vitreoretinal degeneration
|
MONDO_0020248 |
|
Jervell and Lange-Nielsen syndrome 2
|
MONDO_0012871 |
[Any Jervell and Lange-Nielsen syndrome in which the cause of the disease is a mutation in the KCNE1 gene.] |
Jervell and Lange-Nielsen syndrome
|
MONDO_0002441 |
[An autosomal recessive inherited syndrome caused by mutations in the KCNE1 and KCNQ1 genes. It is characterized by congenital hearing loss and arrhythmia. It is a form of long QT syndrome.] |
long QT syndrome 5
|
MONDO_0013372 |
[Any long QT syndrome in which the cause of the disease is a mutation in the KCNE1 gene.] |
dilated cardiomyopathy 1J
|
MONDO_0011541 |
[An extremely rare autosomal dominant syndrome described in two families to date and characterized by moderate to severe sensorineural hearing loss manifesting during childhood, and associated with late-onset dilated cardiomyopathy that generally progresses to heart failure.] |
xeroderma pigmentosum group A
|
MONDO_0010210 |
[Any xeroderma pigmentosum in which the cause of the disease is a mutation in the XPA gene.] |
heparin cofactor 2 deficiency
|
MONDO_0012876 |
|
xeroderma pigmentosum group E
|
MONDO_0010213 |
[An autosomal recessive genetic disorder caused by mutations in the DDB2 gene. This disease exhibits the mildest degree of sun sensitivity of all xeroderma pigmentosum complementation groups, although individuals are at high risk for skin cancer.] |
xeroderma pigmentosum group D
|
MONDO_0010212 |
[Any xeroderma pigmentosum in which the cause of the disease is a mutation in the ERCC2 gene.] |
xeroderma pigmentosum group F
|
MONDO_0010215 |
[Any xeroderma pigmentosum in which the cause of the disease is a mutation in the ERCC4 gene.] |
xeroderma pigmentosum variant type
|
MONDO_0010214 |
[Xeroderma pigmentosum variant is a milder subtype of xeroderma pigmentosum (XP), a rare genetic photodermatosis characterized by severe sun sensitivity and an increased risk of skin cancer.] |
autosomal recessive osteopetrosis
|
MONDO_0019026 |
[An autosomal recessive form of osteopetrosis caused by mutation(s) in at least 8 genes related to osteoclast function. This condition is characterized by the failure of osteoclasts to resorb bone, resulting in impaired bone modeling/remodeling, and skeletal fragility despite increased bone mass; it is also associated with hematopoietic insufficiency, hypocalcemia, disturbed tooth eruption, nerve entrapment syndromes, and growth impairment. Some cases are also associated with progressive neurological deterioration.] |
osteopetrosis
|
MONDO_0017198 |
[Osteopetrosis, also known as marble bone disease, is a descriptive term that refers to a group of rare, heritable disorders of the skeleton characterized by increased bone density on radiographs.] |
Norrie disease
|
MONDO_0010691 |
[A rare X-linked genetic vitreoretinal condition characterized by abnormal retinal development with congenital blindness. Common associated manifestations include sensorineural hearing loss and developmental delay, intellectual disability and/or behavioral disorders.] |
hyperparathyroidism
|
MONDO_0001741 |
[Hyperfunction of the parathyroid glands resulting in the overproduction of parathyroid hormone. It may be primary or secondary; primary hyperparathyroidism is caused by parathyroid adenoma, parathyroid hyperplasia, parathyroid carcinoma, and multiple endocrine neoplasia. It is associated with hypercalcemia and hypophosphatemia. Signs and symptoms include weakness, fatigue, nausea, vomiting, constipation, depression, bone pain, osteoporosis, cystic bone lesions, and kidney stones. Secondary hyperparathyroidism is caused by the chronic stimulation of the parathyroid glands in patients with chronic renal failure, rickets, and malabsorption syndromes.] |
encephalopathy due to sulfite oxidase deficiency
|
MONDO_0019358 |
[Encephalopathy due to sulfite oxidase deficiency is a rare neurometabolic disorder characterized by seizures, progressive encephalopathy and lens dislocation.] |
glaucoma
|
MONDO_0005041 |
[Increased pressure in the eyeball due to obstruction of the outflow of aqueous humor.] |
GTP cyclohydrolase I deficiency
|
MONDO_0100184 |
[A disease characterized by a deficiency in GTP cyclohydrolase I, which leads to a consequent reduction in BH4 and reduces the activity of three BH4-cofactor dependent enzymes - phenylalanine hydroxylase, tyrosine hydroxylase, and tryptophan hydroxylase. GTP cyclohydrolase I deficiency encompasses a spectrum of disease that includes autosomal dominant and autosomal recessive forms, with severity correlating with the residual enzyme activity. Individuals who are heterozygous for pathogenic variants in GCH1 have symptoms ranging from none (due to reduced penetrance) to dopa-responsive dystonia, which is the most common presentation in symptomatic cases, to rarer neurological presentations such as adult-onset "benign" parkinsonism, various types of focal dystonia, and symptoms simulating cerebral palsy or spastic paraplegia. Hyperphenylalaninemia is absent, and patients respond well to treatment with levodopa. Individuals who are homozygous or compound heterozygous for pathogenic variants in GCH1 typically present with hyperphenylalaninemia, often identified by newborn screening, and severe neurological features and due to very low or undetectable enzyme activity. Treatment with levodopa, BH4, and 5-hydroxytryptophan can improve the symptoms but does not prevent development of severe encephalopathy. Rare cases of GTP cyclohydrolase I deficiency with a phenotype that is intermediate in severity between dopa-responsive dystonia and the severe autosomal recessive form have also been described, supporting the existence a phenotypic spectrum of disease.] |